Scott Dehm
@scottdehm
Professor @UMNcancer studying steroid hormones, androgen receptors, and #ProstateCancer genomes. Apogee Enterprises Chair in Cancer Research . Views=mine.
It is this time of the Year again: 10 TOP TRANSLATIONAL PAPERS IN GU ONCOLOGY! 1/ Prostate Paper 1 Fonseca et al. introduced a machine-learning approach that predicts whether patients with #mCRPC have sufficient ctDNA% for informative genotyping. This study addresses a critical…
Fascinating work by Chen et al in uncovering new metabolomics of SPOP-mutant prostate cancer, we review here @EAntonarakis @scottdehm nature.com/articles/s4301…
Check out our new work exploring AR biology in advanced prostate cancer: tinyurl.com/2s39jh8b. We found that tumours expressing a specific AR variant (ARv567es) have a distinct transcriptomic profile and are resistant to androgen deprivation and bipolar androgen therapy
🧪 Dr. @scottdehm and collaborators including @huang_lab, @EAntonarakis, & @mishabeltran showed that double-negative #CRPC cells express genes defining basal, club, and hillock epithelial cells from benign #prostate. @PNASNews | bit.ly/4gI7fH3
Thrilled to share a project that we envisioned over a decade ago to perform high purity/high specificity molecular analysis of circulating tumor cells! Led by the brilliant @marina_sharifi and @JSperger @AACR Funded by @PCF_Science @NIH @CDMRP
Now online in @CD_AACR: High-Purity Circulating Tumor Cell RNA Sequencing Identifies #ProstateCancer Lineage Phenotypes Prognostic for Clinical Outcomes - by @marina_sharifi, @JSperger, Shuang Zhao, @JoshLangMD et al. doi.org/10.1158/2159-8… @UWCarbone @UWMadison #LiquidBiopsy
Excited to share a new paper by postdoc Dr. Kiel Tietz @UMNCancer! CPSF1 inhibition promotes widespread use of intergenic polyadenylation sites and impairs glycolysis in prostate cancer cells: Cell Reports cell.com/cell-reports/f… Work funded by @CDMRP and @NCICancerBio
In memory of Dr. Felix Feng. Thank you @EUplatinum for honoring our beloved colleague and friend, gone too soon. We miss you Felix @MaryFengMD @nlinmd @PCF_Science sciencedirect.com/science/articl…
The two faces of FOXA1 muts in PCa. Congrats to Justin Hwang for this revised classification of FOXA1 alts in PCa. Different FOXA1 classes have different biologic behaviors, clinical outcomes & racial clustering, esp. Class 1B and 2. @UMNcancer @scottdehm aacrjournals.org/clincancerres/…
PROSTATE Paper 2 Franseschini et al. developed a targeted DNA methylation assay for the detection of neuroendocrine prostate cancer using plasma cell-free DNA with an AUC > 0.93. Their assay also quantifies tumor content and offers a phenotype evidence score, which reflects…
PROSTATE Paper 3 Knutson et al. developed the AR-ctDETECT assay to detect ctDNA in limiting plasma cfDNA from pts w/ #mCRPC in @ALLIANCE_org A031201 ph3 trial of enzalutamide w/ or w/o abiraterone. The ctDNA assay was able to prognosticate outcomes, as pts w/ mCRPC who were…
AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients out in Nature Communications nature.com/articles/s4146… This study introduces a custom circulating tumor DNA (ctDNA) 🧬sequencing assay, AR-ctDETECT, designed to…
Susan Halabi representing @DukeGUCancer at #ASCO24 presenting our @ALLIANCE_org clinical genetic model using the @scottdehm AR-ctDETECT ctDNA assay. The new Halabi+ model! @DukeCancer